Back to Search Start Over

Impact of antiangiogenic treatment on the erectile function in patients with advanced renal cell carcinoma.

Authors :
Marcon J
Trottmann M
Rodler S
Becker AJ
Stief CG
Bauer RM
Casuscelli J
Source :
Andrologia [Andrologia] 2021 Feb; Vol. 53 (1), pp. e13881. Date of Electronic Publication: 2020 Nov 09.
Publication Year :
2021

Abstract

We longitudinally assessed erectile function as well as the willingness to use pro-erectile treatment in a cohort on AAT for advanced RCC. Thirty-seven patients with advanced RCC completed the five-item version of the International Index of Erectile Function (IIEF-5) and other interview items before (T0) and 12 weeks into therapy (T12) with AAT. Patients were further asked if they were willing to use and pay out-of-pocket for on-demand treatment with phosphodiesterase-5-inhibitors (PDE-5i). Statistical analysis was performed using nonparametric hypothesis testing. The IIEF-5 score at T12 was significantly decreased compared with T0 (p < .001). Subjective patient satisfaction regarding their sexual lives was associated with higher IIEF-5 scores at both time points (p = .006 and p = .03, respectively). At T12, subjective sexual contentment showed a nonsignificant trend towards decline (p = .074). Patients who opted for medical treatment of ED showed significantly better IIEF-5 scores at both time points compared with the rest of the cohort (p < .001 and p = .005, respectively). In summary, AAT seems to have a negative effect on erectile function in RCC patients, however, the role of psychosocial issues warrants further elucidation. Affected patients may benefit from a proactive approach promoting medical treatment of erectile dysfunction during AAT.<br /> (© 2020 The Authors. Andrologia published by Wiley-VCH GmbH.)

Details

Language :
English
ISSN :
1439-0272
Volume :
53
Issue :
1
Database :
MEDLINE
Journal :
Andrologia
Publication Type :
Academic Journal
Accession number :
33167067
Full Text :
https://doi.org/10.1111/and.13881